News und Analysen
3 Unstoppable Dividend Stocks to Buy Right Now
Income investors won't be happy with dividends that aren't sustainable. Instead, they want to own dividend stocks that they can depend on.
Three Motley Fool contributors identified stocks that
Why Shares of BioLife Solutions Plummeted This Week
Shares of BioLife Solutions (NASDAQ: BLFS) were down more than 37% for the week, as of 3:15 p.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The healthcare company's
Why Shares of Sage Therapeutics Slumped This Week
Shares of Sage Therapeutics (NASDAQ: SAGE) were down by more than 40% for the week at 11 a.m. on Friday, according to data provided by S&P Global Market Intelligence. The pharmaceutical company's
Does Pfizer Stock Belong in a Dividend Portfolio?
Investing becomes an easier process the moment that you shift from a trading mindset to an ownership approach. That transformation begins when you realize that behind every stock ticker, there's a
2 Beaten-Down Dividend Stocks to Buy
Dividend stocks can be great additions to anyone's portfolio, and it's even better to buy quality ones when they're down. While the market has roared back this year following a downturn in 2022, it
Should Value Investors Buy This Healthcare Stock?
Value investing is a rather popular investing strategy. Seeing as almost everyone enjoys buying great products at discounted prices, it isn't surprising that we would also like to get good deals on
2 Beaten-Down Stocks That Still Aren't Worth Buying
As conventional investment wisdom has it, it's best to buy low and sell high. However, that only works when you have solid reasons to believe a company's shares will bounce back meaningfully after a
If You'd Invested $25,000 in Viatris in 2020, This Is How Much You Would Have Today
Viatris (NASDAQ: VTRS) spun off from Pfizer and merged with Mylan back in 2020. It's a generic drugmaker with a diverse, global business that serves patients and customers in over 165 countries and
Down 96%, Is Invitae Stock a Buy?
Fool.com contributor Parkev Tatevosian offers investors an earnings review of Invitae (NYSE: NVTA) and lets you know if the beaten-down growth stock is a buy.
*Stock prices used were the afternoon
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Is AT&T Stock a Buy Now?
U.S. telecom company AT&T (NYSE: T) might be the latest example of a stock that seems like it can't go much lower -- shares of the company trade for roughly $14 each, their lowest price since the
Why Novavax Stock Blasted 8% Higher Today
There's nothing like a surge in a deadly disease to encourage investors back into a noted healthcare stock. This dynamic benefited biotech Novavax (NASDAQ: NVAX) on Thursday.
It was also on the back
Why Shares of MacroGenics Are Jumping Thursday
Shares of MacroGenics (NASDAQ: MGNX) were up more than 24% as of 11:45 a.m. on Thursday after the biotech company announced second-quarter earnings. The stock is down more than 7% so far this year.
Is Abbott Laboratories Stock a Buy Now?
Abbott Laboratories (NYSE: ABT) posted its latest earnings numbers last month, and there's reason to be optimistic about the business. Although a drop in COVID testing means sales are down overall
Will UnitedHealth Group Be a Trillion-Dollar Stock by 2030?
In the realm of investing, market capitalization is a good but not perfect way to gauge the success of a business. Sure, sometimes companies are overvalued. But a company's market value can at least
Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around?
Biogen (NASDAQ: BIIB) is an intriguing stock right now. Its business has struggled to generate growth in recent years, but some recent catalysts could turn things around. For starters, the company's
My Oh My, Merck Stock Is a No-Brainer Income Stock to Buy
Investing for income may never be the most exciting investment strategy in the world. But as long as a company doesn't cut or suspend its dividend, it can be a profitable approach -- and some
Could Vertex Pharmaceuticals Stock Help You Become a Millionaire?
Biotech company Vertex Pharmaceuticals (NASDAQ: VRTX) has made for a solid investment over the past decade, more than quadrupling in value during that period. The stock generated fantastic returns
Want Rising Dividend Income? Buy Amgen Stock
The cost of living is getting more and more expensive. This is because inflation steadily diminishes the value of the U.S. dollar over time, and the purchasing power of said dollar as a result.
One
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Is Merck Stock a Buy Now?
Merck (NYSE: MRK) has performed poorly in the stock market this year, with the drugmaker's shares down by 5%. But zooming out helps put a different spin on this story as the pharmaceutical giant has
3 Top Biotech Stocks Defying the Bear Market
If you look at the S&P 500, which is up more than 18% this year, or the Nasdaq Composite, which is up more than 34% in 2023, it appears the markets are booming. If you look specifically at biotech